CASIF (CASI Pharmaceuticals) Additional Paid-In Capital: $722.31 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
26 GF Score
Price $0.14
GF Value $1.04
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Additional Paid-In Capital?

CASI Pharmaceuticals CASIF 26 Additional Paid-In Capital is $722.31 Mil as of Jun. 2026. GuruFocus rates CASIF with a GF Score™ of 26/100 and a GF Value™ of $1.04 (Possible Value Trap). The stock has 7 warning signs investors should review.


CASI Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2025 ($715.73 Mil) to Dec. 2025 ($722.24 Mil) and increased from Dec. 2025 ($722.24 Mil) to Jun. 2026 ($722.31 Mil).

CASI Pharmaceuticals's annual additional paid-in capital increased from Dec. 2023 ($695.79 Mil) to Dec. 2024 ($713.30 Mil) and increased from Dec. 2024 ($713.30 Mil) to Dec. 2025 ($722.24 Mil).

CASI Pharmaceuticals Additional Paid-In Capital Related Terms

CASI Pharmaceuticals Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Additional Paid-In Capital Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 696.22 691.77 695.79 713.30 722.24

CASI Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 699.37 713.30 715.73 722.24 722.31
CASIF
26GF Score
CASI Pharmaceuticals Inc CASIF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $722.31 Mil mean?
CASI Pharmaceuticals (CASIF) has a Additional Paid-In Capital of $722.31 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Additional Paid-In Capital too high?
CASI Pharmaceuticals' current Additional Paid-In Capital is $722.31 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Additional Paid-In Capital compare to CMND and VBIO?
CASI Pharmaceuticals' Additional Paid-In Capital of $722.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Additional Paid-In Capital is $722.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.04, compared to a current price of $0.14 — trading 86.5% below its estimated fair value. The current Additional Paid-In Capital is $722.31 Mil. CASI Pharmaceuticals' overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Additional Paid-In Capital is $722.31 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.14 is trading 86.5% below its estimated GF Value™ of $1.04. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Additional Paid-In Capital: $722.31 Mil
  • GF Value™: $1.04 vs. price of $0.14 (86.5% below fair value)
  • GF Score™: 26/100 with 7 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
26GF Score

Get the complete analysis for CASIF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$1.04
GF Value